October 3, 2025 · Form 4 insider transaction
Kulkarni Samarth bought 49,500 shares of CRISPR Therapeutics AG at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
This option was granted on October 3, 2025 with respect to 49,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.